The FDA has granted traditional approval to Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Galegenimab, an anti-HtrA1 antibody, does not slow the progression of geographic atrophy, according to research published in the American Journal of Ophthalmology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback